Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Rezultati

Naziv:	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
Autori :	Ray, Kausik K.; ...; Ristić, Arsen D. ; ...; (broj koautora 24)
Godina:	2019
Publikacija:	The lancet. Diabetes & endocrinology
ISSN:	2213-8587 Lancet Diabetes & Endocrinology Pretraži identifikator
Izdavač:	London : The Lancet, Diabetes & Endocrinology
Tip rezultata:	Naučni članak
Kolacija:	vol. 7 br. 8 str. 618-628
DOI:	10.1016/S2213-8587(19)30158-5
WoS-ID:	000475553300016
Scopus-ID:	2-s2.0-85068931122
PMID:	31272931
URI:	https://enauka.gov.rs/handle/123456789/818042
URL:	https://www.thelancet.com/journals/landia/article/PIIS2213-8587(19)30158-5/abstract
Projekat:	Sanofi Regeneron Pharmaceuticals
Izvor metapodataka:	(Preuzeto iz Nasi u WoS)
M-kategorija:	21a+M21a+ - Vodeći međunarodni časopis kategorije M21a+

292
SCOPUS^TM

134
PubMed Central^TM

136
OpenCitations

281
WEB OF SCIENCE^TM

Alt metrika

Dimensions

Unpaywall

Rezultati na eNauka su zaštićeni autorskim pravima i sva prava su zadržana, osim ako nije drugačije naznačeno.